Presentation description

Every year, 0.8-2 million patients contract a surgical site infection (SSI), increasing patient mortality 2-11 fold. SSIs are caused by an individual's own skin bacteria. Hospitals use chlorohexidine gluconate (CHG) products, like CHG IV port and wound dressings that release CHG into the skin via diffusion. We hypothesized that the quantity of CHG released from antimicrobial products would determine the product's effectiveness in reducing skin bacteria. We tested our hypothesis using a pig model